Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 26

1.

Efficacy of human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine against cervical infection and precancer caused by oncogenic HPV types (PATRICIA): final analysis of a double-blind, randomised study in young women.

Paavonen J, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter D, Kitchener H, Castellsague X, Teixeira JC, Skinner SR, Hedrick J, Jaisamrarn U, Limson G, Garland S, Szarewski A, Romanowski B, Aoki FY, Schwarz TF, Poppe WA, Bosch FX, Jenkins D, Hardt K, Zahaf T, Descamps D, Struyf F, Lehtinen M, Dubin G; HPV PATRICIA Study Group.

Lancet. 2009 Jul 25;374(9686):301-14. doi: 10.1016/S0140-6736(09)61248-4. Epub 2009 Jul 6. Erratum in: Lancet. 2010 Sep 25;376(9746):1054.

PMID:
19586656
[PubMed - indexed for MEDLINE]
2.

Immunogenicity testing in human papillomavirus virus-like-particle vaccine trials.

Schiller JT, Lowy DR.

J Infect Dis. 2009 Jul 15;200(2):166-71. doi: 10.1086/599988. No abstract available.

PMID:
19519255
[PubMed - indexed for MEDLINE]
Free PMC Article
3.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in generally HPV-naive women aged 16-26 years.

Brown DR, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Wheeler CM, Perez G, Koutsky LA, Tay EH, Garcia P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, Sings HL, James M, Hesley TM, Barr E.

J Infect Dis. 2009 Apr 1;199(7):926-35. doi: 10.1086/597307.

PMID:
19236279
[PubMed - indexed for MEDLINE]
Free Article
4.

The impact of quadrivalent human papillomavirus (HPV; types 6, 11, 16, and 18) L1 virus-like particle vaccine on infection and disease due to oncogenic nonvaccine HPV types in sexually active women aged 16-26 years.

Wheeler CM, Kjaer SK, Sigurdsson K, Iversen OE, Hernandez-Avila M, Perez G, Brown DR, Koutsky LA, Tay EH, García P, Ault KA, Garland SM, Leodolter S, Olsson SE, Tang GW, Ferris DG, Paavonen J, Steben M, Bosch FX, Dillner J, Joura EA, Kurman RJ, Majewski S, Muñoz N, Myers ER, Villa LL, Taddeo FJ, Roberts C, Tadesse A, Bryan J, Lupinacci LC, Giacoletti KE, James M, Vuocolo S, Hesley TM, Barr E.

J Infect Dis. 2009 Apr 1;199(7):936-44. doi: 10.1086/597309.

PMID:
19236277
[PubMed - indexed for MEDLINE]
Free Article
5.

Correlation between direct ELISA, single epitope-based inhibition ELISA and pseudovirion-based neutralization assay for measuring anti-HPV-16 and anti-HPV-18 antibody response after vaccination with the AS04-adjuvanted HPV-16/18 cervical cancer vaccine.

Dessy FJ, Giannini SL, Bougelet CA, Kemp TJ, David MP, Poncelet SM, Pinto LA, Wettendorff MA.

Hum Vaccin. 2008 Nov-Dec;4(6):425-34. Epub 2008 Nov 11.

PMID:
18948732
[PubMed - indexed for MEDLINE]
Free Article
6.

Epidemiology and natural history of human papillomavirus infections and type-specific implications in cervical neoplasia.

Bosch FX, Burchell AN, Schiffman M, Giuliano AR, de Sanjose S, Bruni L, Tortolero-Luna G, Kjaer SK, Muñoz N.

Vaccine. 2008 Aug 19;26 Suppl 10:K1-16. doi: 10.1016/j.vaccine.2008.05.064. Review.

PMID:
18847553
[PubMed - indexed for MEDLINE]
7.

Rationale and design of a community-based double-blind randomized clinical trial of an HPV 16 and 18 vaccine in Guanacaste, Costa Rica.

Herrero R, Hildesheim A, Rodríguez AC, Wacholder S, Bratti C, Solomon D, González P, Porras C, Jiménez S, Guillen D, Morales J, Alfaro M, Cyr J, Morrisey K, Estrada Y, Cortés B, Morera LA, Freer E, Schussler J, Schiller J, Lowy D, Schiffman M; Costa Rica Vaccine Trial (CVT) Group.

Vaccine. 2008 Sep 2;26(37):4795-808. doi: 10.1016/j.vaccine.2008.07.002. Epub 2008 Jul 18.

PMID:
18640170
[PubMed - indexed for MEDLINE]
Free PMC Article
8.

Evaluation of systemic and mucosal anti-HPV16 and anti-HPV18 antibody responses from vaccinated women.

Kemp TJ, García-Piñeres A, Falk RT, Poncelet S, Dessy F, Giannini SL, Rodriguez AC, Porras C, Herrero R, Hildesheim A, Pinto LA; Costa Rica Vaccine Trial (CVT) Group.

Vaccine. 2008 Jul 4;26(29-30):3608-16. doi: 10.1016/j.vaccine.2008.04.074. Epub 2008 May 19.

PMID:
18541349
[PubMed - indexed for MEDLINE]
Free PMC Article
9.

Efficacy of a prophylactic adjuvanted bivalent L1 virus-like-particle vaccine against infection with human papillomavirus types 16 and 18 in young women: an interim analysis of a phase III double-blind, randomised controlled trial.

Paavonen J, Jenkins D, Bosch FX, Naud P, Salmerón J, Wheeler CM, Chow SN, Apter DL, Kitchener HC, Castellsague X, de Carvalho NS, Skinner SR, Harper DM, Hedrick JA, Jaisamrarn U, Limson GA, Dionne M, Quint W, Spiessens B, Peeters P, Struyf F, Wieting SL, Lehtinen MO, Dubin G; HPV PATRICIA study group.

Lancet. 2007 Jun 30;369(9580):2161-70. Erratum in: Lancet. 2007 Oct 20;370(9596):1414.

PMID:
17602732
[PubMed - indexed for MEDLINE]
10.

Quadrivalent vaccine against human papillomavirus to prevent anogenital diseases.

Garland SM, Hernandez-Avila M, Wheeler CM, Perez G, Harper DM, Leodolter S, Tang GW, Ferris DG, Steben M, Bryan J, Taddeo FJ, Railkar R, Esser MT, Sings HL, Nelson M, Boslego J, Sattler C, Barr E, Koutsky LA; Females United to Unilaterally Reduce Endo/Ectocervical Disease (FUTURE) I Investigators.

N Engl J Med. 2007 May 10;356(19):1928-43.

PMID:
17494926
[PubMed - indexed for MEDLINE]
Free Article
11.

Quadrivalent vaccine against human papillomavirus to prevent high-grade cervical lesions.

FUTURE II Study Group.

N Engl J Med. 2007 May 10;356(19):1915-27.

PMID:
17494925
[PubMed - indexed for MEDLINE]
Free Article
12.

Highly effective detection of human papillomavirus 16 and 18 DNA by a testing algorithm combining broad-spectrum and type-specific PCR.

van Doorn LJ, Molijn A, Kleter B, Quint W, Colau B.

J Clin Microbiol. 2006 Sep;44(9):3292-8.

PMID:
16954263
[PubMed - indexed for MEDLINE]
Free PMC Article
13.

Sustained efficacy up to 4.5 years of a bivalent L1 virus-like particle vaccine against human papillomavirus types 16 and 18: follow-up from a randomised control trial.

Harper DM, Franco EL, Wheeler CM, Moscicki AB, Romanowski B, Roteli-Martins CM, Jenkins D, Schuind A, Costa Clemens SA, Dubin G; HPV Vaccine Study group.

Lancet. 2006 Apr 15;367(9518):1247-55.

PMID:
16631880
[PubMed - indexed for MEDLINE]
Free Article
14.

Human papillomavirus capsid antibody response to natural infection and risk of subsequent HPV infection in HIV-positive and HIV-negative women.

Viscidi RP, Snyder B, Cu-Uvin S, Hogan JW, Clayman B, Klein RS, Sobel J, Shah KV.

Cancer Epidemiol Biomarkers Prev. 2005 Jan;14(1):283-8.

PMID:
15668510
[PubMed - indexed for MEDLINE]
Free Article
15.

Efficacy of a bivalent L1 virus-like particle vaccine in prevention of infection with human papillomavirus types 16 and 18 in young women: a randomised controlled trial.

Harper DM, Franco EL, Wheeler C, Ferris DG, Jenkins D, Schuind A, Zahaf T, Innis B, Naud P, De Carvalho NS, Roteli-Martins CM, Teixeira J, Blatter MM, Korn AP, Quint W, Dubin G; GlaxoSmithKline HPV Vaccine Study Group.

Lancet. 2004 Nov 13-19;364(9447):1757-65.

PMID:
15541448
[PubMed - indexed for MEDLINE]
16.

Determinants of human papillomavirus 16 serological conversion and persistence in a population-based cohort of 10 000 women in Costa Rica.

Wang SS, Schiffman M, Herrero R, Carreon J, Hildesheim A, Rodriguez AC, Bratti MC, Sherman ME, Morales J, Guillen D, Alfaro M, Clayman B, Burk RD, Viscidi RP.

Br J Cancer. 2004 Oct 4;91(7):1269-74.

PMID:
15292929
[PubMed - indexed for MEDLINE]
Free PMC Article
17.

Seroreactivity to human papillomavirus (HPV) types 16, 18, or 31 and risk of subsequent HPV infection: results from a population-based study in Costa Rica.

Viscidi RP, Schiffman M, Hildesheim A, Herrero R, Castle PE, Bratti MC, Rodriguez AC, Sherman ME, Wang S, Clayman B, Burk RD.

Cancer Epidemiol Biomarkers Prev. 2004 Feb;13(2):324-7.

PMID:
14973086
[PubMed - indexed for MEDLINE]
Free Article
18.

Genital human papillomavirus infection: incidence and risk factors in a cohort of female university students.

Winer RL, Lee SK, Hughes JP, Adam DE, Kiviat NB, Koutsky LA.

Am J Epidemiol. 2003 Feb 1;157(3):218-26. Erratum in: Am J Epidemiol. 2003 May 1;157(9):858.

PMID:
12543621
[PubMed - indexed for MEDLINE]
Free Article
19.

A controlled trial of a human papillomavirus type 16 vaccine.

Koutsky LA, Ault KA, Wheeler CM, Brown DR, Barr E, Alvarez FB, Chiacchierini LM, Jansen KU; Proof of Principle Study Investigators.

N Engl J Med. 2002 Nov 21;347(21):1645-51.

PMID:
12444178
[PubMed - indexed for MEDLINE]
Free Article
20.

Risk factors for subsequent cervicovaginal human papillomavirus (HPV) infection and the protective role of antibodies to HPV-16 virus-like particles.

Ho GY, Studentsov Y, Hall CB, Bierman R, Beardsley L, Lempa M, Burk RD.

J Infect Dis. 2002 Sep 15;186(6):737-42. Epub 2002 Aug 28.

PMID:
12198606
[PubMed - indexed for MEDLINE]
Free Article

Display Settings:

Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk